Cidara Therapeutics Future Growth
Future criteria checks 1/6
Cidara Therapeutics is forecast to grow earnings and revenue by 56.8% and 16% per annum respectively while EPS is expected to grow by 61.9% per annum.
Key information
56.8%
Earnings growth rate
61.9%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | 16.0% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 23 Apr 2024 |
Recent future growth updates
Recent updates
We Think Cidara Therapeutics (NASDAQ:CDTX) Can Easily Afford To Drive Business Growth
Sep 28Lacklustre Performance Is Driving Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) 39% Price Drop
Apr 17Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Are Reducing Their Forecasts For This Year
Mar 25We're Hopeful That Cidara Therapeutics (NASDAQ:CDTX) Will Use Its Cash Wisely
Mar 14Cidara spikes on $11M milestone payment from partner Mundipharma
Oct 04Cidara begins dosing of antiviral CD388 in trial for preventing influenza
Sep 13Cidara Therapeutics GAAP EPS of -$0.19 beats by $0.09, revenue of $6.22M beats by $0.01M
Aug 09Industry Analysts Just Made A Captivating Upgrade To Their Cidara Therapeutics, Inc. (NASDAQ:CDTX) Revenue Forecasts
Dec 17Rainbows and Unicorns: Cidara Therapeutics, Inc. (NASDAQ:CDTX) Analysts Just Became A Lot More Optimistic
Aug 17Is Cidara Therapeutics (NASDAQ:CDTX) Weighed On By Its Debt Load?
Aug 04Cidara Therapeutics: Rezafungin Data Could Bring Value
Jul 20We Think Some Shareholders May Hesitate To Increase Cidara Therapeutics, Inc.'s (NASDAQ:CDTX) CEO Compensation
Jun 17Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 58 | -4 | -56 | -29 | 3 |
12/31/2025 | 46 | -19 | -61 | -40 | 3 |
12/31/2024 | 39 | -35 | -76 | -18 | 1 |
12/31/2023 | 64 | -23 | -23 | -22 | N/A |
9/30/2023 | 57 | -31 | -31 | -31 | N/A |
6/30/2023 | 85 | -8 | -1 | -1 | N/A |
3/31/2023 | 83 | -9 | -16 | -16 | N/A |
12/31/2022 | 64 | -34 | -29 | -28 | N/A |
9/30/2022 | 61 | -33 | -22 | -22 | N/A |
6/30/2022 | 28 | -63 | -62 | -62 | N/A |
3/31/2022 | 54 | -44 | -47 | -47 | N/A |
12/31/2021 | 50 | -42 | -25 | -25 | N/A |
9/30/2021 | 46 | -47 | -21 | -21 | N/A |
6/30/2021 | 41 | -47 | -24 | -24 | N/A |
3/31/2021 | 12 | -74 | -41 | -41 | N/A |
12/31/2020 | 12 | -75 | -55 | -54 | N/A |
9/30/2020 | 10 | -67 | -59 | -58 | N/A |
6/30/2020 | 27 | -47 | -28 | -28 | N/A |
3/31/2020 | 23 | -42 | -27 | -27 | N/A |
12/31/2019 | 21 | -41 | -29 | -29 | N/A |
9/30/2019 | 19 | -39 | -27 | -27 | N/A |
6/30/2019 | N/A | -56 | -57 | -56 | N/A |
3/31/2019 | N/A | -69 | -59 | -59 | N/A |
12/31/2018 | N/A | -69 | -57 | -57 | N/A |
9/30/2018 | N/A | -70 | -53 | -53 | N/A |
6/30/2018 | N/A | -69 | -54 | -54 | N/A |
3/31/2018 | N/A | -59 | -50 | -50 | N/A |
12/31/2017 | N/A | -56 | -50 | -50 | N/A |
9/30/2017 | N/A | -57 | N/A | -52 | N/A |
6/30/2017 | N/A | -57 | N/A | -46 | N/A |
3/31/2017 | N/A | -52 | N/A | -43 | N/A |
12/31/2016 | N/A | -48 | N/A | -40 | N/A |
9/30/2016 | N/A | -44 | N/A | -35 | N/A |
6/30/2016 | N/A | -41 | N/A | -34 | N/A |
3/31/2016 | N/A | -35 | N/A | -31 | N/A |
12/31/2015 | N/A | -32 | N/A | -26 | N/A |
9/30/2015 | N/A | -27 | N/A | -22 | N/A |
6/30/2015 | N/A | -21 | N/A | -18 | N/A |
3/31/2015 | N/A | -18 | N/A | -13 | N/A |
12/31/2014 | N/A | -12 | N/A | -8 | N/A |
9/30/2014 | N/A | -8 | N/A | -5 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CDTX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CDTX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CDTX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CDTX's revenue (16% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: CDTX's revenue (16% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CDTX's Return on Equity is forecast to be high in 3 years time